Ergomed plc Board Changes (7317C)

TIDMERGO

RNS Number : 7317C

Ergomed plc

02 October 2018

PRESS RELEASE

FOR IMMEDIATE RELEASE

Board Changes

Michael Spiteri appointed Non-Executive Director to help drive digitization strategy

London, UK - 2 October 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces two Board changes with immediate effect.

Michael Spiteri joins the Board as Non-Executive Director. Michael has nearly 30 years' experience working in information technology and digital transformation. At Santander's UK Corporate and Commercial Banking business, he is responsible for digital strategy, process transformation and digital implementation across all areas of the business including automation and machine learning. Prior to Santander, Michael held partner roles at Elixirr Partners LLP and PricewaterhouseCoopers LLP and senior executive roles at Accenture and IBM as well as senior management roles at HCL Axon and Oracle with a focus on financial services clients. Michael received a BSc in Mechanical Engineering from Paisley College of Technology.

Andrew Mackie is stepping down as Chief Business Officer and Board member following the Company's announcement in April to shift its strategy to focus on services.

Peter George, Chairman of Ergomed, said: "The use of digital technology to drive both efficiency and accuracy is a strategic priority for Ergomed, particularly in our pharmacovigilance business. As a leader in the world of digitization, automation and AI, Michael's experience and counsel will be invaluable to our Board as we optimise the Group's operations and drive growth. I look forward to his input and welcome him to the team.

"I would also like to recognize Andrew's contribution to Ergomed over the last three years as an executive and for several years before that as a consultant. We wish him well in his future endeavours."

Michael Spiteri, Non-Executive Director of Ergomed, said: "Ergomed is at a key juncture as it embraces and takes advantage of the opportunities presented by automation and AI. I'm delighted to be joining the Ergomed Board and I am looking forward to contributing to the roll-out of its digitization strategy".

Additional Information

Michael William Spiteri (57) has held the following directorships/partnerships in the past five years:

Current

Behavioural Innovation Ltd: Director

Previous

PriceWaterHouseCoopers LLP: LLP Member

Elixirr Partners LLP: LLP Member

Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Michael Spiteri's appointment.

- Ends -

Enquiries:

 
 Ergomed plc                                        Tel: [phone] 
 Stephen Stamp (Chief Executive Officer) 
 
 Numis Securities Limited                          Tel: [phone] 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
 James Black (Joint Broker) 
 
 
 Consilium Strategic Communications - for          Tel: [phone] 
  UK enquiries 
 Chris Gardner / Mary-Jane Elliott               [e-mail] 
  Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European               Tel: [phone] 
  enquiries 
 Anne Hennecke 
 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOALLFSVIELFIIT

(END) Dow Jones Newswires

October 02, 2018 09:47 ET (13:47 GMT)